Tackling Alzheimer’s Session 1

Moderated by George Vradenburg, Co-Chair, Davos Alzheimer’s Collaborative

With 9.9 million new cases of dementia globally each year, the type of collective action witnessed during the COVID-19 pandemic is urgently needed.

What policies, practices and partnerships can help to develop new diagnostics and treatments for Alzheimer’s?

This session is associated with the Davos Alzheimer's Collaborative, convened by the Global CEO Initiative on Alzheimer's Disease (CEOi) and the World Economic Forum.

The first part of this session is open to the public online; the second is only accessible via TopLink.

Speakers

  • George Vrandenburg III
    Chairman of the Board, Davos Alzheimer's Collaborative

  • Haruo Naito
    Representative Corporate Officer and Chief Executive Officer, Eisai Co. Ltd

  • Margaret Chan
    Founding Dean and Vanke Chair Professor, Vanke School of Public Health, Tsinghua University

  • Andrea Pfeifer
    Chief Executive Officer, AC Immune SA

  • Arnaud Bernaert
    Head, Health Security Solutions, SICPA SA

Knapsack

Knapsack Creative is an award-winning Squarespace design and SEO agency helping small businesses turn their websites into growth engines. We specialize in building sleek, high-converting Squarespace sites powered by the StoryBrand framework; so your message is clear, your brand stands out, and your site actually generates leads.

From consultants and creatives to financial professionals and service-based businesses, we design with strategy at the core: blending modern design, SEO optimization, and conversion-focused storytelling. Our team has launched hundreds of Squarespace websites that don’t just look beautiful, they win trust and deliver results.

Whether you need a one-day website build, a full redesign, or an SEO strategy to rank in local search, Knapsack Creative makes it simple, fast, and effective to get online and grow.

👉 Trusted by 1,000+ businesses nationwide. Featured Squarespace Experts.

https://www.knapsackcreative.com
Previous
Previous

Positive Data on Eli Lilly’s Alzheimer’s Drug and Many Other Catalysts Suggest Cassava Sciences’ Run is Just Getting Started

Next
Next

Tackling Alzheimer’s Session 2